Table 4.
SICH and 3-months outcomes.
| Outcomes | Prospective 3–4 5 h n/N (%) aOR (95% CI) | Prospective within 3 h n/N (%) aOR (95% CI) | p-valuesa | Retrospective within 3 h n/N (%) aOR (95% CI) | p-valuesb |
|---|---|---|---|---|---|
| SICH (SITS-MOST)c | 17/ 1082 (1.57) | 49/ 2953 (1.66) | 0.956 | 60/ 3391 (1.77) | 0.811 |
| Adjusted OR | 1.08 (0.61–1.90) | – | 0.787 | 0.91 (0.61–1.35) | 0.639 |
| SICH (ECASS II)d | 42/ 1074 (3.91) | 97/ 2946 (3.29) | 0.395 | 131/ 3369 (3.89) | 0.231 |
| Adjusted OR | 1.46 (0.99–2.15) | – | 0.053 | 0.87 (0.65–1.15) | 0.331 |
| SICH (NINDS)d | 59/ 1081 (5.46) | 144/ 2950 (4.88) | 0.509 | 194/ 3386 (5.7) | 0.149 |
| Adjusted OR | 1.35 (0.98–1.87) | – | 0.068 | 0.89 (0.70–1.12) | 0.326 |
| 3 months (mRS 0–1) | 399/ 782 (51.0) | 1109/ 2230 (49.7) | 0.562 | 1450/ 2951 (49.1) | 0.692 |
| Adjusted OR | 0.87 (0.72–1.05) | – | 0.159 | 0.96 (0.84–1.09) | 0.514 |
| 3 months (mRS 0–2) | 512/ 782 (65.5) | 1453/ 2230 (65.2) | 0.908 | 1878/ 2951 (63.4) | 0.272 |
| Adjusted OR | 0.81 (0.67–0.99) | – | 0.044 | 1.01 (0.88–1.15) | 0.925 |
| 3 months mortality | 93/ 801 (11.6) | 251/ 2267 (11.1) | 0.726 | 333/ 3021 (11.0) | 0.990 |
| Adjusted OR | 1.30 (0.98–1.73) | – | 0.066 | 1.10 (0.90–1.34) | 0.339 |
SICH: symptomatic intracerebral haemorrhage; mRS: modified Rankin scale; aOR: adjusted odds ratio.
For the prospective 3–4.5 h compared to prospective ≤3 h cohort. Multivariate analysis adjusted for age, sex, baseline NIHSS, history of diabetes mellitus, hyperlipidaemia and atrial fibrillation and treatment with Clopidogel at baseline.
For ≤3 h prospective cohort compared to ≤3 h retrospective cohort. Multivariate analysis adjusted for age, baseline NIHSS, history of TIA, atrial fibrillation, and smoking, aspirin, antihypertensive and statin treatment at baseline.
A local or remote parenchymal haemorrhage type 2 on the 22- to 36-h post-treatment imaging scan or earlier if clinically indicated, combined with a neurological worsening of ≥4 points between baseline and 24 h, or leading to death.
Any intracerebral haemorrhage on any post-treatment imaging scans combined with NIHSSS worsening ≥4 points between baseline and 7d, or leading to death.
Any intracerebral haemorrhage on any post-treatment imaging scans combined with any decline in neurologic status as measured by NIHSS between baseline and 7d, or leading to death.